Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Potenciadores de lantánidos en radioterapia del cáncer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20180817001
Publicado:
07/09/2018
Caducidad:
08/09/2019
Resumen:
Una universidad alemana ha desarrollado una tecnología para acoplar compuestos de lantánido a nanopartículas poliméricas de ácido láctico (PLGA). Estas nanopartículas son biodegradables y pueden aplicarse para intensificar la radiación en el tratamiento del cáncer. La dosis de radiación acumulada se reduce, lo que se traduce en una carga de radiación menor para el paciente. La tecnología puede aplicarse en equipos de rayos X comunes. La universidad busca socios con el fin de establecer acuerdos de licencia exclusivos y no exclusivos para continuar con el desarrollo y comercializar la tecnología en Reino Unido o Francia.

Details

Tittle:
Lanthanide-Enhancers in the radiotherapy of cancer.
Summary:
A German university has developed a technology for coupling lanthanide compounds in lactic acid polymer (PLGA) nanoparticles. These nanoparticles are biodegradable and can be applied to intensify radiation in cancer tumour therapy. By this the cumulative radiation dose is reduced, thus causes a lower radiation burden for the patient. The university is looking for exclusive or non-exclusive licensing for further developing and marketing in United Kingdom or France; option agreements are possible.
Description:
The medical centre of the German university in the institute of radio-oncology and radiation therapy has developed a technology for coupling lanthanide compounds in PLGA nanoparticles.

In Europe almost one in three people suffer from cancer during the course of their life.
The radiation therapy is widely used as a method of treatment. Cancer cells will be harmed more, because they are more sensitive than healthy cells to ionizing radiation. Nevertheless, to reduce the cancer cell growth, significantly high doses of radiation have to be used, but this leads to unwanted side-effects. Locally acting enhancers can increase the radiation, so that the cumulative dose is reduced, and at the same time the ionizing effect in the tumour tissue itself is increased. The radiation enhancer should not be toxic for the healthy tissue.

The new technology uses lanthanides compounds, which are coupled to biodegradable lactic acid polymers to intensify radiation. The problem of unintended polymer accumulation in the body is avoided by the nanoparticles´ biodegradability. These particles can be introduced locally into the tumour tissue. For the radiation-potentiating effect it is sufficient to use only photon radiation, which is produced by common X-ray machines, thus additional neutron radiation is not necessary. X-ray machines usually exist in doctors´ surgeries, so that more widespread application of radiation enhancer is possible.
The lanthanide radiation enhancer can be disposed in all cancer treatments, which use radiation therapy. They ensure a more efficient combat against the tumour tissue by local enhancement of the radiation in the tumour, and thus a lower burden for the patient through a reduced cumulative dose.

The university seeks to license the new technology to companies capable to further develop the technology towards a marketable product.
Advantages and Innovations:
· Increased efficiency through locally increased radiation dose
· less side effects by decreased cumulative dose
· applicable for common X-ray machines
· The lactic acid polymer (PLGA) is an approved adjuvant for
pharmaceutical applications
· PLGA-coupled lanthanide nanoparticles are biodegradable
and non-toxic.
Stage of Development:
Under development/lab tested
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
EU patent granted. Valid in France, UK -Y- Germany.

Partner sought

Type and Role of Partner Sought:
The university is looking for a pharmaceutic company that has the expertise and capacity to further develop the lanthanide nanoparticles towards a marketable product. Ideally the company has already established a good position in the medical market in France or United Kingdom, and is also interested in manufacturing and distribution of the product. Exclusive and non-exclusive licenses are considered. Option agreements for prior evaluating and testing the technology are also possible.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Dissemination

Restrict dissemination to specific countries:
France, United Kingdom

Keywords

Technology Keywords:
06002001 Bioquímica / biofísica
06001003 Citología, cancerología, oncología
06001012 Investigaciones médicas
06004 Micro y nanotecnología relacionada con las ciencias biológicas
06001013 Tecnología médica / ingeniería biomédica